论文部分内容阅读
近年来,乙型肝炎病毒(HBV)的分子生物学研究进展很快,人们对抗-HBe的理解加深。在1984年病毒性肝炎国际讨论会上,有学者提出:抗-HBe在肝病中可能是一种好现象,但也可能是HBVDNA整合的一种表现。尔后,台湾Liaw氏提出血清抗-HBe与原发性肝细胞癌(PHC)的癌变组织学变化相关。但迄今尚未见有这方面的研究报道。本文检测了104例PHC患者和96例其它恶性肿瘤患者(对照组)的血清抗-HBe与其它HBV感染指标,以探讨血清抗-HBe在PHC患者病程发展过程中的临床意义。现报告如下:
In recent years, the molecular biology of hepatitis B virus (HBV) has progressed rapidly and people’s understanding of anti-HBe has deepened. At the 1984 International Symposium on Viral Hepatitis, some scholars suggested that anti-HBe may be a good phenomenon in liver disease, but it may also be a manifestation of HBV DNA integration. Later, Liaws of Taiwan proposed serum anti-HBe correlated with histological changes of hepatocellular carcinoma (PHC). However, so far no studies have been reported in this area. This article tested the serum anti-HBe and other HBV infection indicators in 104 patients with PHC and 96 patients with other malignant tumors (control group) to explore the clinical significance of serum anti-HBe in the course of development of PHC patients. The report is as follows: